Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.responsebio.com
Number of Employees: 56
Year Founded: 1980
Total Amount Raised (CAD mm)†: 77.46
Total Rounds of Funding**:16
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing, and on-site environmental testing markets. The POC and on-site diagnostic tests are non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges, and/or dipsticks. It provides RAMP system, which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company’s RAMP tests are used in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, and environmental detection of West Nile Virus; and biodefense applications, including the rapid on-site detection of anthrax, smallpox, ricin, and botulinum toxin. Response Biomedical Corp. sells its products through distributors primarily in the United States, Asia, Latin and South America, Europe, the Middle East, and Canada. The company was founded in 1980 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
9.2
Market Capitalization
12.1
EBITDA
(0.9)
EBIT
(1.8)
Cash & ST Invst.
1.3
P/Diluted EPS Before Extra
NM
Net Income
(2.2)
Total Debt
0.5
Price/Tang BV
NM
Capital Expenditure
(0.1)
Total Assets
10.4
Total Debt/EBITDA
NM
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Sep-30-2016 TEV and Market Cap are calculated using a close price as of Dec-01-2016

Key Professionals
Name
Title
Steen, Barbara R. Kinnaird 
Chief Executive Officer and Director
Eastwood, Megan
Director of Operations
Carter, Angela
Director of Customer and Business Development
Tsonis, Anastasios
Director of Finance

Key Board Members
Name
Title
Steen, Barbara R. Kinnaird 
Chief Executive Officer and Director
Chan, Caroline
Director
Liu, Hui 
Director
Wang, Jonathan J. 
Director
Xu, Ken 
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
1781 - 75th Avenue West | Vancouver, BC | V6P 6P2 | Canada
Phone: 604-456-6010   Fax: 604-456-6066

Parent Company
1077801 B.C. Ltd.

Prior Investors
3M Company (NYSE:MMM), Caduceus Asia Partners, Caduceus Private Investments III, L.P., Hangzhou Lizhu Medical Instrument & Reagent Co. Ltd., Joinstar Biomedical Technology Co., Ltd., OrbiMed Advisors LLC (Jonathan J. Wang), OrbiMed Associates III, LP, OrbiMed Capital LLC, SVB Financial Group (OTCPK:SIVB.Q)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Response Point of Care Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-16-2016
Nov-29-2016
Merger/Acquisition
Target
Response Biomedical Corp.
1077801 B.C. Ltd.
3M Company (NYSE:MMM),OrbiMed Advisors LLC,OrbiMed Capital LLC,SVB Financial Group (OTCPK:SIVB.Q),Joinstar Biomedical Technology Co., Ltd.,Hangzhou Lizhu Medical Instrument & Reagent Co. Ltd. Seller Funds:Caduceus Asia Partners, Caduceus Private Investments III, L.P., OrbiMed Associates III, LP
-
May-30-2016
Jun-17-2016
Private Placement
Target
Response Biomedical Corp.
OrbiMed Advisors LLC,Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108)

0.50
May-20-2016
Nov-30-2016
Shelf Registration
Target
Response Biomedical Corp.


0.38
Oct-15-2014
Dec-12-2014
Private Placement
Target
Response Biomedical Corp.
Joinstar Biomedical Technology Co., Ltd.,Hangzhou Lizhu Medical Instrument & Reagent Co. Ltd.

1.89
Feb-11-2014
Feb-11-2014
Private Placement
Target
Response Biomedical Corp.
SVB Financial Group (OTCPK:SIVB.Q)

2.50
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Dec-02-2016
Executive/Board Changes - Other
Response Biomedical Corp. Announces Executive Resignations
Dec-02-2016
Delistings
Response Biomedical Files Form 15
Nov-30-2016
Shelf Registration Filings
Response Biomedical Corp. has closed its Shelf Registration dated October 24, 2007 in the amount of $10.505 million.
Nov-29-2016
Delistings
Response Biomedical Expects To Be Delisted From TSX On Or About December 2, 2016
Nov-29-2016
M&A Transaction Closings
1077801 B.C. Ltd. completed the acquisition of Response Biomedical Corp (TSX:RBM) (OTC:RPBIF).

M&A Advisors
Blake, Cassels & Graydon LLP, Bloom Burton & Co. Inc., Dorsey & Whitney LLP, Wilson Sonsini Goodrich & Rosati, P.C.


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Blake, Cassels & Graydon LLP, Bloom Burton & Co. Inc., Dorsey & Whitney LLP, Wilson Sonsini Goodrich & Rosati, P.C.
Private Placement Advisors
Blake, Cassels & Graydon LLP, Bloom Burton & Co. Inc., Borden Ladner Gervais LLP, Delafield Hambrecht, Inc., Advisory Arm, Dorsey & Whitney LLP, Ernst & Young LLP, Gowling WLG International Limited, Haywood Securities Inc., Trout Capital LLC, Wilson Sonsini Goodrich & Rosati, P.C.
Public Offering Advisors
Borden Ladner Gervais LLP, Dorsey & Whitney LLP, Ernst & Young LLP (Canada)


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 08, 2023 12:18 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
28
GlobalData

Jun 08, 2023 02:50 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
27
GlobalData

Mar 06, 2023 11:00 PM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
27
GlobalData

Dec 08, 2022 12:11 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
40
GlobalData

Oct 14, 2022 02:27 AM
Response Biomedical Corp.
Response Biomedical Corp - Medical Devices Product Pipeline Summary
Reports
41
GlobalData

Sep 15, 2022 10:34 AM
Response Biomedical Corp.
Response Biomedical Corp - Medical Devices Product Pipeline Summary
Reports
41
GlobalData

Sep 12, 2022 03:31 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
48
GlobalData

Jun 13, 2022 03:09 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
48
GlobalData

Mar 10, 2022 01:55 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
47
GlobalData

Dec 10, 2021 01:40 AM
Response Biomedical Corp.
Response Biomedical Corp - Strategic SWOT Analysis Review
Reports
51



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Medical Strategy GmbH, Asset Management Arm
0
(102,040)
Sectoral Asset Management Inc.
0
(28,571)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Botulinum Toxin Test, D-dimer, POC TB Diagnostic Assay (Future), RAMP Anthrax Test, RAMP CK-MB, RAMP Dengue Test, RAMP Influenza A + B Assay, RAMP Myoglobin, RAMP NT-proBNP Test, RAMP Procalcitonin Test, RAMP Reader, RAMP RSV Assay, RAMP Staph A Test, RAMP West Nile Virus Test, Ricin Test, Small Pox Test, Troponin I


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Dec-05-2016
-
Response Biomedical Corp.
SEDAR
Material Change Report
13 KB
Dec-02-2016
-
Response Biomedical Corp.
SEDAR
Management Proxy Materials
415 KB
Dec-02-2016
Nov-29-2016
Response Biomedical Corp.
SEC
8-K (2.01, 3.03, 5.01, 5.02, 8.01, 9.01)
71 KB
Nov-30-2016
-
Response Biomedical Corp.
SEDAR
Management Proxy Materials
463 KB
Nov-29-2016
-
Response Biomedical Corp.
SEDAR
Change in Corporate Structure
18 KB
Nov-29-2016
-
Response Biomedical Corp.
SEDAR
News Releases
55 KB
Nov-15-2016
-
Response Biomedical Corp.
SEDAR
Material Change Report
545 KB
Nov-15-2016
-
Response Biomedical Corp.
SEDAR
Documents Affecting the Rights of Security Holders
585 KB
Nov-15-2016
Nov-10-2016
Response Biomedical Corp.
SEC
8-K (2.02, 9.01)
181 KB
Nov-14-2016
Sep-30-2016
Response Biomedical Corp.
SEDAR
Interim Financial Statements
473 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Wang MBA, Ph.D., Jonathan J.  (Director)
Nov-29-2016
Common Shares
(71,396)
-
Other Disposition
(100.00)
Form 4
OrbiMed Advisors LLC
Nov-29-2016
Common Shares
(5,788,459)
-
Other Disposition
(100.00)
Form 4
-
Nov-29-2016
Common Shares
(3,604,266)
-
Other Disposition
-
Form 4
-
Nov-29-2016
Common Shares
(34,291)
-
Other Disposition
-
Form 4
-
Nov-29-2016
Common Shares
(2,149,902)
-
Other Disposition
-
Form 4
Severson, Clinton H. (Former Director)
Nov-29-2016
Common Shares
(74,742)
-
Sale to Issuer
(100.00)
Form 4
Keegan Ph.D., Joseph D. (Former Director)
Nov-29-2016
Common Shares
(73,850)
-
Sale to Issuer
(100.00)
Form 4
Holler M.D., Anthony F. (Former Treasurer)
Nov-29-2016
Common Shares
50,154
-
Other Acquisition
(100.00)
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Steen, Barbara R. Kinnaird 
Chief Executive Officer and Director
604-456-6010
604-456-6066
bkinnaird@responsebio.com
Chan, Caroline
Director
604-456-6010
604-456-6066
-
Liu, Hui 
Director
604-456-6010
604-456-6066

Wang, Jonathan J. 
Director
604-456-6010
+86 21 6163 2570

Xu, Ken 
Director
604-456-6010
604-456-6066

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Steen, Barbara R. Kinnaird 
Chief Executive Officer and Director
604-456-6010
604-456-6066
bkinnaird@responsebio.com
Eastwood, Megan
Director of Operations
604-456-6010
604-456-6066
-
Carter, Angela
Director of Customer and Business Development
604-456-6010
604-456-6066
-
Tsonis, Anastasios
Director of Finance
604-456-6010
604-456-6066
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
